Novartis

Novartis bid to block generic Entresto in US suffers setback
Pharmaphorum
Thu, 12/5/24 - 11:01 am
Novartis
Entresto
legal
generics
heart failure
Novartis wagers billions of dollars on PTC Huntington’s drug
BioPharma Dive
Mon, 12/2/24 - 11:26 am
Novartis
PTC Therapeutics
Huntington's disease
PTC518
Olema stock surges on Novartis deal and $250M private placement
Investing.com
Mon, 12/2/24 - 11:09 am
Olema
Novartis
breast cancer
Novartis plots more than 100 layoffs in New Jersey as part of rework to Xolair, cancer combo field sales teams
Fierce Pharma
Tue, 11/26/24 - 10:26 pm
Novartis
layoffs
New Jersey
Xolair
Novartis buys Kate Therapeutics, eyeing $55B CGT market opportunity by 2030
BioSpace
Thu, 11/21/24 - 11:54 am
Novartis
Kate Therapeutics
M&A
gene therapy
Novartis: launch of Morphosys drug by could be 2027 or later
Pharma Live
Thu, 11/21/24 - 11:43 am
Novartis
pelabresib
MorphoSys
obesity
Novartis taps Vyriad’s viral vectors to develop in vivo T cell editing
Fierce Biotech
Wed, 11/20/24 - 08:44 pm
Novartis
Vyriad
viral vectors
t cell therapy
CAR-T
Novartis, Ratio sign radiopharmaceutical pact to the tune of $745M biobucks
Fierce Biotech
Mon, 11/18/24 - 11:32 am
Novartis
radiopharmaceuticals
Ration Therapeutics
biobucks
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
CP Wire
Thu, 11/14/24 - 10:25 pm
Azurity
Danziten
Ph+ CML
FDA
Novartis
Tasigna
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Thu, 11/14/24 - 07:28 pm
Azurity
Danziten
Ph+ CML
FDA
Novartis
Tasigna
Novartis pays Schrödinger $150M, bets billions on the back end to form drug discovery pact
Fierce Biotech
Tue, 11/12/24 - 11:02 am
Novartis
Schrödinger
R&D
Autolus enters CAR-T race with FDA approval for Aucatzyl
Fierce Pharma
Mon, 11/11/24 - 11:49 am
Autolus Therapeutics
CAR-T
FDA
Aucatzyl
Gilead Sciences
Novartis
relapsed or refractory B-cell precursor acute lymphoblastic leukemia
Among 2024’s modest M&A action, cancer, immunology and neuroscience deals trickle in
Pharma Voice
Thu, 11/7/24 - 11:12 am
M&A
Vertex Pharmacuticals
Alpine Immune Sciences
Eli Lilly
Morphic
Novartis
MorphoSys
Mariana Oncology
AstraZeneca
Fusion Pharmaceuticals
Lundbeck
Longboard Pharmaceuticals
AbbVie
Aliada Therapeutics
In defense of radioligand therapies, Novartis fired off patent lawsuits against Lilly and other rivals
Fierce Pharma
Mon, 11/4/24 - 11:21 am
Novartis
legal
radiopharmaceuticals
radioligands
patents
Big Pharma earnings hang hope on the next generation of blockbusters
Pharma Voice
Thu, 10/31/24 - 09:19 am
Pfizer
JNJ
Biogen
Novartis
earnings
Novartis gets FDA okay for frontline use of Scemblix in CML
Pharmaphorum
Wed, 10/30/24 - 11:38 am
Novartis
CML
Scemblix
FDA
Novartis' $2.9B MorphoSys bet stumbles as safety signal delays filing by years
Fierce Biotech
Tue, 10/29/24 - 11:44 am
Novartis
MorphoSys
M&A
AML
pelabresib
Monte Rosa joins with Novartis in ‘molecular glue’ drug deal
BioPharma Dive
Mon, 10/28/24 - 11:36 am
Novartis
molecular glue degrader
Monte Rosa
Novartis eyes year-end filing in US for Fabhalta in C3G
Pharmaphorum
Mon, 10/28/24 - 10:17 am
Novartis
Fabalta
kidney disease
C3 glomerulopathy
Novartis falls short in legal effort to undo FDA approval of MSN's Entresto generic
Fierce Pharma
Thu, 10/17/24 - 08:50 pm
Novartis
generics
Entresto
MSN Pharmaceuticals
legal

Pages